Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 116

1.

Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial.

Koehler F, Koehler K, Deckwart O, Prescher S, Wegscheider K, Kirwan BA, Winkler S, Vettorazzi E, Bruch L, Oeff M, Zugck C, Doerr G, Naegele H, Störk S, Butter C, Sechtem U, Angermann C, Gola G, Prondzinsky R, Edelmann F, Spethmann S, Schellong SM, Schulze PC, Bauersachs J, Wellge B, Schoebel C, Tajsic M, Dreger H, Anker SD, Stangl K.

Lancet. 2018 Sep 22;392(10152):1047-1057. doi: 10.1016/S0140-6736(18)31880-4. Epub 2018 Aug 25.

PMID:
30153985
2.

Long-term treatment with ivabradine over 12months in patients with chronic heart failure in clinical practice: Effect on symptoms, quality of life and hospitalizations.

Zugck C, Störk S, Stöckl G; RELIf-CHF study investigators.

Int J Cardiol. 2017 Aug 1;240:258-264. doi: 10.1016/j.ijcard.2017.03.131. Epub 2017 Apr 11.

PMID:
28408104
3.

[Indications and Clinical Implications of the Use of the Cardiac Markers BNP and NT-proBNP].

Luchner A, von Haehling S, Holubarsch C, Keller T, Knebel F, Zugck C, Laufs U.

Dtsch Med Wochenschr. 2017 Mar;142(5):346-355. doi: 10.1055/s-0042-117368. Epub 2017 Mar 10. Review. German.

PMID:
28282683
4.

Predicting hospitalization and mortality in patients with heart failure: The BARDICHE-index.

Uszko-Lencer NHMK, Frankenstein L, Spruit MA, Maeder MT, Gutmann M, Muzzarelli S, Osswald S, Pfisterer ME, Zugck C, Brunner-La Rocca HP; TIME-CHF Investigators.

Int J Cardiol. 2017 Jan 15;227:901-907. doi: 10.1016/j.ijcard.2016.11.122. Epub 2016 Nov 9.

PMID:
27915084
5.

Periodontitis in Chronic Heart Failure.

Fröhlich H, Herrmann K, Franke J, Karimi A, Täger T, Cebola R, Katus HA, Zugck C, Frankenstein L.

Tex Heart Inst J. 2016 Aug 1;43(4):297-304. doi: 10.14503/THIJ-15-5200. eCollection 2016 Aug.

6.

Long-term outcome of patients with and without super-response to CRT-D.

Franke J, Keppler J, Abadei AK, Bajrovic A, Meme L, Zugck C, Raake PW, Zitron E, Katus HA, Frankenstein L.

Clin Res Cardiol. 2016 Apr;105(4):341-8. doi: 10.1007/s00392-015-0926-0. Epub 2015 Oct 23.

PMID:
26497005
7.

[The Wearable Cardioverter-Defibrillator (WCD)].

Helms TM, Müller A, Schwab JO, Bänsch D, Karle C, Klingenheben T, Zugck C, Perings C.

Herzschrittmacherther Elektrophysiol. 2015 Jun;26(2):129-33. doi: 10.1007/s00399-015-0365-7. Epub 2015 May 5. German.

PMID:
25939989
8.

[Is heart rate adequately controlled in chronic systolic heart failure patients in Germany? results from a nationwide survey (INDICATE)].

Zugck C, Martinka P, Stöckl G, Tschöpe C, Störk S.

Dtsch Med Wochenschr. 2015 Mar;140(5):e48-55. doi: 10.1055/s-0041-100608. Epub 2015 Mar 3. German.

PMID:
25734683
9.

Etiology-specific assessment of predictors of long-term survival in chronic systolic heart failure.

Franke J, Zugck C, Hochadel M, Hack A, Frankenstein L, Zhao JD, Ehlermann P, Nelles M, Zeymer U, Winkler R, Zahn R, Katus HA, Senges J.

Int J Cardiol Heart Vasc. 2015 Feb 26;7:61-68. doi: 10.1016/j.ijcha.2015.01.015. eCollection 2015 Jun 1.

10.

Gender aspects in clinical presentation and prognostication of chronic heart failure according to NT-proBNP and the Heart Failure Survival Score.

Franke J, Lindmark A, Hochadel M, Zugck C, Koerner E, Keppler J, Ehlermann P, Winkler R, Zahn R, Katus HA, Senges J, Frankenstein L.

Clin Res Cardiol. 2015 Apr;104(4):334-41. doi: 10.1007/s00392-014-0786-z. Epub 2014 Nov 6.

PMID:
25373384
11.

Ivabradine treatment in a chronic heart failure patient cohort: symptom reduction and improvement in quality of life in clinical practice.

Zugck C, Martinka P, Stöckl G.

Adv Ther. 2014 Sep;31(9):961-74. doi: 10.1007/s12325-014-0147-3. Epub 2014 Aug 27.

12.

Characteristics, management modalities and outcome in chronic systolic heart failure patients treated in tertiary care centers: results from the EVIdence based TreAtment in Heart Failure (EVITA-HF) registry.

von Scheidt W, Zugck C, Pauschinger M, Hambrecht R, Bruder O, Hartmann A, Rauchhaus M, Zahn R, Brachmann J, Tebbe U, Neumann T, Strasser RH, Böhm M, Störk S, Hochadel M, Heidemann P, Senges J.

Clin Res Cardiol. 2014 Dec;103(12):1006-14. doi: 10.1007/s00392-014-0743-x. Epub 2014 Jul 23.

PMID:
25052361
13.

[Differentiated antiplatelet therapy for acute coronary syndromes].

Schäfer A, Arntz HR, Boudriot E, Garlichs C, Hoffmann S, Ince H, Klingenheben T, Weil J, Zugck C, Helms TM, Silber S.

Dtsch Med Wochenschr. 2014 Jan;139(4):152-8. doi: 10.1055/s-0033-1359911. Epub 2014 Jan 15. Review. German.

PMID:
24430955
14.

Left atrial appendage occlusion in atrial fibrillation after intracranial hemorrhage.

Horstmann S, Zugck C, Krumsdorf U, Rizos T, Rauch G, Geis N, Hardt S, Veltkamp R.

Neurology. 2014 Jan 14;82(2):135-8. doi: 10.1212/WNL.0000000000000022. Epub 2013 Dec 6.

15.

Homoarginine--an independent marker of mortality in heart failure.

Atzler D, Rosenberg M, Anderssohn M, Choe CU, Lutz M, Zugck C, Böger RH, Frey N, Schwedhelm E.

Int J Cardiol. 2013 Oct 12;168(5):4907-9. doi: 10.1016/j.ijcard.2013.07.099. Epub 2013 Jul 24. No abstract available.

PMID:
23890923
16.

A genome-wide association study identifies 6p21 as novel risk locus for dilated cardiomyopathy.

Meder B, Rühle F, Weis T, Homuth G, Keller A, Franke J, Peil B, Lorenzo Bermejo J, Frese K, Huge A, Witten A, Vogel B, Haas J, Völker U, Ernst F, Teumer A, Ehlermann P, Zugck C, Friedrichs F, Kroemer H, Dörr M, Hoffmann W, Maisch B, Pankuweit S, Ruppert V, Scheffold T, Kühl U, Schultheiss HP, Kreutz R, Ertl G, Angermann C, Charron P, Villard E, Gary F, Isnard R, Komajda M, Lutz M, Meitinger T, Sinner MF, Wichmann HE, Krawczak M, Ivandic B, Weichenhan D, Gelbrich G, El-Mokhtari NE, Schreiber S, Felix SB, Hasenfuß G, Pfeufer A, Hübner N, Kääb S, Arbustini E, Rottbauer W, Frey N, Stoll M, Katus HA.

Eur Heart J. 2014 Apr;35(16):1069-77. doi: 10.1093/eurheartj/eht251. Epub 2013 Jul 12.

PMID:
23853074
17.

Clinical characteristics, morbidity, and prognostic value of concomitant coronary artery disease in idiopathic dilated cardiomyopathy.

Frankenstein L, Hees H, Taeger T, Froehlich H, Dösch A, Cebola R, Zugck C, Katus HA.

Clin Res Cardiol. 2013 Oct;102(10):771-80. doi: 10.1007/s00392-013-0589-7. Epub 2013 Jun 26.

PMID:
23800786
18.

Association between spironolactone added to beta-blockers and ACE inhibition and survival in heart failure patients with reduced ejection fraction: a propensity score-matched cohort study.

Frankenstein L, Katus HA, Grundtvig M, Hole T, de Blois J, Schellberg D, Atar D, Zugck C, Agewall S; Norwegian Heart Failure Registry steering committee.

Eur J Clin Pharmacol. 2013 Oct;69(10):1747-55. doi: 10.1007/s00228-013-1512-x. Epub 2013 Jun 7.

PMID:
23743778
19.

EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot).

Maggioni AP, Dahlström U, Filippatos G, Chioncel O, Crespo Leiro M, Drozdz J, Fruhwald F, Gullestad L, Logeart D, Fabbri G, Urso R, Metra M, Parissis J, Persson H, Ponikowski P, Rauchhaus M, Voors AA, Nielsen OW, Zannad F, Tavazzi L; Heart Failure Association of the European Society of Cardiology (HFA).

Eur J Heart Fail. 2013 Jul;15(7):808-17. doi: 10.1093/eurjhf/hft050. Epub 2013 Mar 28.

20.

Supplemental Content

Loading ...
Support Center